1384875-17-5

Basic information

• Product Name: N,N-bis[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide
• Synonyms: N,N-bis[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide
• CAS NO: 1384875-17-5
• Molecular Weight: 572.67
• Mol File: 1384875-17-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N,N-bis[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-bis[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide(1384875-17-5)
• EPA Substance Registry System: N,N-bis[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide(1384875-17-5)

Safety Data

• Hazardous Substances Data: 1384875-17-5(Hazardous Substances Data)

Upstream product

• 1384875-64-2 7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonic acid amide 
• 1261358-78-4 4-(4-benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1261358-63-7 4-(4,7-diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1261354-55-5 7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-carboxylic acid tert-butyl ester 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 858121-94-5 4-(bromomethyl)-1,1-difluorocyclohexane 
• 74-96-4 ethyl bromide 
• 1384875-65-3 4-(4-sulfamoyl-4,7-diazaspiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester 

Relevant articles and documents

NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF

The invention relates to compounds of general Formula (I), Wherein R1, R2, R3, R4, R5, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use - alone or in combination with one or more other pharmaceutically active compounds- in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disesase, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.